Drug Trial Radar · NCT00125593
Study of Heart and Renal Protection
Last checked: Nov 20, 2026Latest source record: Feb 1, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9,438
Actual
Start
Jun 2003
Primary completion
Aug 2010
Study completion Aug 2010
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Merck Sharp & Dohme LLC; Schering-Plough; National Health and Medical Research Council, Australia; British Heart Foundation; Medical Research Council
- First posted
- Aug 1, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The chief aim of SHARP was to determine whether lowering blood LDL cholesterol with simvastatin (20mg) plus ezetimibe (10mg) daily could safely reduce the risk of coronary heart disease, non-hemorrhagic stroke and the need for revascularization procedures in patients with chronic kidney disease (CKD). It also aimed to assess whether lowering LDL cholesterol reduced the rate of loss of renal function in people with CKD who had not commenced dialysis treatment.
Conditions
- Kidney Disease, Chronic
Interventions
Simvastatin 20 mgDrug
Once daily
Ezetimibe 10mgDrug
Once daily
PlaceboDrug
Once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Key Outcome as Per Statistical Analysis Plan = Major Atherosclerotic Events Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to PlaceboTime frame: Median follow-up 4.9 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.